Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships UT System/UTHSCT: exclusive license covering LTI-03 (royalty-bearing; milestone/diligent-commercialization terms)
Indications
Idiopathic pulmonary fibrosis (IPF)(Phase 2)
Catalysts
— Q4 2026
Status note RENEW trial: Phase 2 multi-center, randomized, double-blind, placebo-controlled; first patient dosed Mar 2026; screening began May 2025. EMA orphan drug designation Jan 2026.
LTI-01
Phase 2 · ActiveModality: proenzyme
Target plasminogen
Partnerships UT System/UTHSCT: exclusive license covering LTI-01
Indications
Loculated pleural effusion(Phase 2)
Status note Phase 2a dose-ranging and Phase 1b completed. Paused indefinitely while resources are prioritized toward LTI-03; resumption timing uncertain.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.